Evolution of the Average Target: Sionna Therapeutics, Inc.

Evolution of the Target Price: Sionna Therapeutics, Inc.

Changes in Analyst Recommendations: Sionna Therapeutics, Inc.

bda984af.JwSMwZT4EVientUY8navsWk1577PEQ_O0ckawME-UMQ.b1f-luK1fznw6qB3lELMwzEFncuMPDiGsLxvr5VUZoBlT--D_Y58B_TZsg~f4d871ff617d2f5be3fd4e30971f7fe1
09-15 Wedbush Raises Price Target on Sionna Therapeutics to $6 From $5, Keeps Neutral Rating MT
08-12 Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says MT
08-11 BTIG Downgrades Sionna Therapeutics to Neutral From Buy MT
08-10 Wedbush Downgrades Sionna Therapeutics to Neutral From Outperform, Adjusts PT to $5 From $53 MT
08-04 Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says MT
05-05 Wedbush Initiates Sionna Therapeutics at Outperform With $53 Price Target MT
12-23 LifeSci Capital Initiates Coverage on Sionna Therapeutics With Outperform Rating, $60 Price Target MT
12-04 Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says MT
12-01 Sionna Therapeutics Shares Lower After RBC Downgrade MT
12-01 RBC Downgrades Sionna Therapeutics to Underperform From Sector Perform, Keeps $24 Price Target, Speculative Risk MT
11-19 BTIG Research Initiates Coverage on Sionna Therapeutics With Buy Rating, $50 Price Target MT
25-10-21 Sionna Therapeutics, Inc. Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis CI
25-09-09 JonesTrading Initiates Sionna Therapeutics at Buy With $46 Price Target MT
25-09-03 Raymond James Initiates Sionna Therapeutics at Strong Buy MT
25-09-03 RBC Capital Initiates Sionna Therapeutics at Sector Perform With $22 Price Target MT
25-03-04 Guggenheim Initiates Sionna Therapeutics at Buy With $45 Price Target MT
25-03-04 Stifel Initiates Sionna Therapeutics at Buy With $32 Price Target MT
25-03-04 TD Cowen Initiates Sionna Therapeutics at Buy MT
25-02-07 Top Midday Gainers MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+327.7%
+11.79%
+27.75%
+21.67%
+24.6%
+11.82%
+21.07%
+46.63%
+6.77%
+20.91%
Average +52.07%
Weighted average by Cap. +20.90%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
4.910USD
Average target price
21.00USD
Spread / Average Target
+327.70%
High Price Target
63.00USD
Spread / Highest target
+1,183.10%
Low Price Target
5.000USD
Spread / Lowest Target
+1.83%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. SION Stock
  4. Consensus Sionna Therapeutics, Inc.